IRIS
FOGARI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.476
AS - Asia 2.675
EU - Europa 2.124
SA - Sud America 269
AF - Africa 79
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.627
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.403
CN - Cina 1.455
SG - Singapore 597
IE - Irlanda 492
UA - Ucraina 434
DE - Germania 277
FI - Finlandia 264
HK - Hong Kong 244
RU - Federazione Russa 207
BR - Brasile 192
VN - Vietnam 164
SE - Svezia 124
FR - Francia 106
IT - Italia 94
GB - Regno Unito 61
ZA - Sudafrica 53
CA - Canada 43
IN - India 43
AR - Argentina 29
BD - Bangladesh 24
IQ - Iraq 19
TR - Turchia 19
CO - Colombia 14
JP - Giappone 13
PK - Pakistan 12
ES - Italia 11
MX - Messico 11
PH - Filippine 11
MY - Malesia 10
NL - Olanda 10
PL - Polonia 9
UZ - Uzbekistan 9
VE - Venezuela 9
AL - Albania 8
ID - Indonesia 8
EC - Ecuador 7
MA - Marocco 6
TN - Tunisia 6
BO - Bolivia 5
CL - Cile 5
IL - Israele 5
IR - Iran 5
JO - Giordania 5
SA - Arabia Saudita 5
AT - Austria 4
BE - Belgio 4
EG - Egitto 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
NI - Nicaragua 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
RO - Romania 3
AZ - Azerbaigian 2
BH - Bahrain 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
TT - Trinidad e Tobago 2
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
KR - Corea 1
KW - Kuwait 1
LC - Santa Lucia 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
TH - Thailandia 1
ZW - Zimbabwe 1
Totale 8.627
Salva come PNG Salva come JPEG
Città #
Jacksonville 537
Dublin 492
Chandler 444
San Jose 355
Nanjing 344
Singapore 288
Dallas 270
Hong Kong 238
Ashburn 235
Beijing 168
Boardman 162
Nanchang 157
Shenyang 120
Hebei 117
Princeton 102
Wilmington 102
Lawrence 98
Changsha 97
Medford 94
Lauterbourg 82
Los Angeles 80
Jiaxing 72
Hangzhou 70
Tianjin 59
Ho Chi Minh City 52
Johannesburg 51
Helsinki 48
Hanoi 46
Buffalo 41
Redondo Beach 33
New York 32
Seattle 30
Moscow 28
Council Bluffs 25
Munich 23
Shanghai 23
São Paulo 23
Toronto 22
Santa Clara 19
Turku 19
Woodbridge 19
Brooklyn 17
Milan 17
Norwalk 15
Frankfurt am Main 14
Orem 14
Fairfield 12
Montreal 11
Stockholm 11
Des Moines 10
London 10
Phoenix 10
Tokyo 10
Ann Arbor 9
Baghdad 9
Belo Horizonte 9
Charlotte 9
Genova 9
Haiphong 9
Jinan 9
Boston 8
Bruino 8
Denver 8
Kunming 8
San Francisco 8
Atlanta 7
Bogotá 6
Ningbo 6
Secaucus 6
Tirana 6
Warsaw 6
Washington 6
Amman 5
Ankara 5
Chennai 5
Chicago 5
Guangzhou 5
Lanzhou 5
New Delhi 5
Nuremberg 5
Pune 5
Tashkent 5
Alcobendas 4
Biên Hòa 4
Brussels 4
Caracas 4
Dhaka 4
Eindhoven 4
Kochi 4
Kuala Lumpur 4
Lahore 4
Lima 4
Medellín 4
Rio de Janeiro 4
Riyadh 4
São Bernardo do Campo 4
Verona 4
Amsterdam 3
Asunción 3
Bishkek 3
Totale 5.733
Salva come PNG Salva come JPEG
Nome #
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 202
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 155
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 152
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 143
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 134
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome 132
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 131
Adipocytokines levels in obese and non-obese subjects, an observational study 129
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 127
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 126
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 123
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 121
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 117
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 116
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome 112
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 112
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus 111
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients 109
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 108
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 107
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 106
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 106
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 105
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 103
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 96
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 94
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 92
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 92
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial 91
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 91
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 91
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 90
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 90
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 90
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 88
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study 88
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 87
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 86
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 84
Effetti di sitagliptin rispetto a glibenclamide in aggiunta a metformina e pioglitazone in pazienti diabetici di tipo 2 84
Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes 84
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 83
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 83
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 83
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 83
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 82
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 82
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 81
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 81
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 81
Effetti di acarbose sui parametri infiammatori e di insulino-resistenza durante un carico orale di grassi 80
Effect of valsartan on insulin sensitivity, leptin, and BMI in hypertensive obese patients 79
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 79
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 79
Efficacy of simvastatin and fenofibrate association in hypercholesterolemic, type 2 diabetic patients compared to monotherapy 79
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 79
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 78
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 78
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 78
Valutazione dei livelli delle metalloproteasi 2 e 9 e dei loro inibitori nella dislipidemia combinata durante terapia con acidi grassi polinsaturi 78
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 78
Una possibilità per migliorare il controllo glicemico e la funzionalità β-celllare durante tre anni di studio: la triplice terapia 77
Variation of some inflammatory biomarkers after the addition of sitagliptin in type 2 diabetic patients not controlled by metformin 77
Exenatide plus metformin compared to metformin alone on beta cell function in type 2 diabetic patients. 76
Exenatide paragonato a glimepiride in aggiunta a metformina sul controllo glicemico, l’insulino-resistenza e i parametri infiammatori in pazienti diabetici di tipo 2 76
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients 76
Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. 76
Modificazioni ultrasonografiche del tessuto adiposo viscerale e sottocutaneo dopo terapia con pioglitazone o glibenclamide in combinazione con rosuvastatina in pazienti diabetici di tipo 2 non ben controllati da metformina 76
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients 76
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. 75
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients 74
Effetti di una combinazione di vildagliptin + metformina su alcuni parametri di funzionalità β-cellulare e di insulino-resistenza in uno studio a 12 mesi 74
Effetti di pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina dopo un carico orale di grassi 74
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 74
Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared to olmesartan or amlodipine monotherapies 73
Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study 73
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type2 diabetic patients not well controlled by metformin 73
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial 72
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. 70
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 70
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 70
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation 70
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 69
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies 69
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 68
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction 66
Studio randomizzato, in doppio cieco, placebo-controllato sugli effetti di sitagliptin sui parametri di insulino-resistenza e di funzionalità beta-cellulare. 66
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 63
Sitagliptin added to previously taken anti-diabetic agents on glycemic control and lipid profile 62
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 62
Valsartan improves plasma leptin in hypertensive obese patients 61
Valutazione dei livelli di MMP-2, MPP-9 e dei loro inibitori nella iperlipemia combinata 60
Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients 58
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months 56
Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2 years study 55
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load 52
The effects of canrenone in patients with metabolic syndrome 52
Totale 8.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.178
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.178
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/2022366 0 0 18 3 3 3 2 25 21 2 58 231
2022/20231.364 130 93 1 91 161 150 0 90 571 17 40 20
2023/2024407 45 98 15 31 41 102 7 39 6 4 13 6
2024/20251.156 10 105 43 48 27 30 88 103 239 16 132 315
2025/20262.529 197 189 300 232 287 120 552 128 197 183 111 33
Totale 8.668